Abstract 5783
Background
Six anti–PD-1/PD-L1 agents have been FDA approved for various cancers. Despite a lack of head-to-head trials, there is a perception that the irAE profiles are comparable between agents. We hypothesized that the irAE profiles vary between anti–PD-1 and anti–PD-L1 agents and among individual agents. Since prospective comparison is unlikely, we conducted a trial-level meta-analysis of irAEs reported in phase I–IV trials evaluating anti–PD-1/L1 agents in various tumor types.
Methods
We analyzed data from 35 manuscripts reporting phase I (n = 18), 2 (n = 15), 3 (n = 9) or 4 (n = 1) trials, comprising 8,730 patients treated with anti–PD-1/PD-L1 monotherapy. The incidence and odds ratios (ORs) for selected clinically relevant irAEs (colitis, elevated AST, hypothyroidism, pneumonitis or rash; any grade and grade ≥3) and irAEs overall were estimated using random-effects models for anti–PD-L1 agents atezolizumab, avelumab and durvalumab; for anti–PD-1 agents nivolumab and pembrolizumab; and as pooled estimates for anti–PD-1 and anti–PD-L1 agents.
Results
The risk of any grade (OR = 4.34) and grade ≥3 rash (OR = 4.38); grade ≥3 hypothyroidism (OR = 2.85); any grade (OR = 2.53) and grade ≥3 colitis (OR = 3.79); and any grade ≥3 irAE (OR = 1.89) was higher with anti–PD-1 vs anti–PD-L1 agents. When comparing the risk of all selected irAEs for each agent with pooled estimates for all other agents combined, atezolizumab had the lowest risk, followed by avelumab; pembrolizumab had a higher risk, except for grade ≥3 elevated AST. In pairwise comparisons, the risks associated with atezolizumab vs avelumab were not significantly different, likewise for nivolumab vs pembrolizumab. The largest decrease in risk for all grade ≥3 irAEs except elevated AST was for avelumab vs pembrolizumab.
Conclusions
Overall, the risk of grade ≥3 irAEs was higher with anti–PD-1 vs anti–PD-L1 agents. Compared with other agents, avelumab had a lower risk of individual grade ≥3 irAEs except elevated AST, whereas atezolizumab had the lowest risk of irAEs of any grade. Limitations include the retrospective nature of the meta-analysis and varied tumor types, trial designs, treatment durations and irAE evaluations.
Clinical trial identification
Editorial acknowledgement
ClinicalThinking, funded by Merck Healthcare KGaA and Pfizer Inc.
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
Merck Healthcare KGaA and Pfizer Inc.
Disclosure
G.P. Sonpavde: Honoraria (self): UpToDate; Advisory / Consultancy: Agensys; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy: Eisai; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck & Co.; Advisory / Consultancy: Novartis; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Speaker Bureau / Expert testimony: Clinical Care Options/NCCN; Speaker Bureau / Expert testimony: Onclive; Speaker Bureau / Expert testimony: Physician Education Resource; Speaker Bureau / Expert testimony: Research to Practice; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Onyx; Research grant / Funding (institution): Pfizer. P. Grivas: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Biocept; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Clovis Oncology; Advisory / Consultancy: Driver, Inc; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Heron; Advisory / Consultancy, Research grant / Funding (institution): Merck & Co.; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: QED Therapeutics; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): Oncogenex. D. Hennessy: Full / Part-time employment: EMD Serono. J.D. Hunt: Full / Part-time employment: EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract